Drugs in pregnancy and their effects on pre- and postnatal development.
D000014:Abnormalities, Drug-Induced; D000477:Alkylating Agents / Q000009:adverse effects; D000818:Animals; D000927:Anticonvulsants / Q000009:adverse effects; D000963:Antimetabolites / Q000009:adverse effects; D002490:Central Nervous System / Q000187:drug effects; D002869:Chromosome Aberrations / Q000139:chemically induced; D025063:Chromosome Disorders; D004247:DNA / Q000096:biosynthesis; D004195:Disease Models, Animal; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D004348:Drug Labeling; D005260:Female; D005865:Gestational Age; D006728:Hormones / Q000009:adverse effects; D006801:Humans; D007231:Infant, Newborn; D008431:Maternal-Fetal Exchange; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy; D012459:Salicylates / Q000009:adverse effects; D013375:Substance Withdrawal Syndrome; D013792:Thalidomide / Q000009:adverse effects; D014481:United States; D014486:United States Food and Drug Administration
D000477:Alkylating Agents; D000927:Anticonvulsants; D000963:Antimetabolites; D006728:Hormones; D012459:Salicylates; D013792:Thalidomide; D004247:DNA